臨床検査68巻7号

2024年07月発行

今月の特集 骨髄腫と類縁疾患の検査学

分子標的薬の進歩と検査への影響と課題

著者： 今井陽一¹

所属機関： ¹獨協医科大学内科学（血液・腫瘍）

ページ範囲：P.872 - P.877

Point

●多発性骨髄腫の治療抗体としてダラツムマブやエロツズマブが導入された．ダラツムマブは初発治療，エロツズマブは再発・難治症例に用いられ，高い治療効果が得られている．

●ヒト免疫グロブリンG（IgG）-κ由来ダラツムマブやエロツズマブ投与では，腫瘍由来Mタンパクが同じIgG-κサブクラスに属する場合に免疫固定電気泳動（IFE）の評価が影響を受ける可能性がある．

●治療抗体による検査への影響の克服のため，VS38c抗体・CD38 Alexa Fluor^®488 nanobodyによる微小残存病変検出方法やDIRAが導入されている．

参考文献

1）de Weers M, Tai YT, van der Veer MS, et al：Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol　186：1840-1848，2011

2）Overdijk MB, Verploegen S, Bögels M, et al：Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs　7：311-321，2015

immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood　128：384-394，2016

4）Dimopoulos MA, Oriol A, Nahi H, et al：Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med　375：1319-1331，2016

5）Palumbo A, Chanan-Khan A, Weisel K, et al：Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med　375：754-766，2016

6）Bahlis NJ, Dimopoulos MA, White DJ, et al：Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia　34：1875-1884，2020

7）Mateos MV, Cavo M, Blade J, et al：Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet　395：132-141，2020

8）Facon T, Kumar S, Plesner T, et al：Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med　380：2104-2115，2019

9）Voorhees PM, Kaufman JL, Laubach J, et al：Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood　136：936-945，2020

10）Dimopoulos MA, Lonial S, White D, et al：Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol　178：896-905，2017

11）Dimopoulos MA, Dytfeld D, Grosicki S, et al：Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med　379：1811-1822，2018

12）Krejcik J, Frerichs KA, Nijhof IS, et al：Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clin Cancer Res　23：7498-7511，2017

13）Flores-Montero J, Sanoja-Flores L, Paiva B, et al：Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia　31：2094-2103，2017

14）Broijl A, de Jong ACM, van Duin M, et al：VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma. Am J Clin Pathol　157：494-497，2022

15）ElMaraashly AH, Tario J, Hillengass J, et al：Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab. Am J Clin Pathol　160：524-532，2023

16）McCudden C, Axel AE, Slaets D, et al：Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med　54：1095-1104，2016

17）Chen S, Kiguchi T, Nagata Y, et al：A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients. Int J Hematol　113：473-479，2021